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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this review is to determine whether APBI has a role in breast conservation therapy for early-stage breast cancer.
B A C K G R O U N D
Description of the condition
Breast cancer is the most common cancer occurring in women.
The lifetime risk of being diagnosed with breast cancer for women
living in Australia and the United States is 1 in 8; it is 1 in 9 for
women living in the United Kingdom (AIHW 2006; ONS 1999;
Ries 2006). Breast cancer is the second most common cause of
cancer death in females.
Historically, mastectomy was the recommended therapeutic op-
tion for all stages of breast cancer.However, large randomised trials
have demonstrated equivalent survival for women with early-stage
disease (Stages I, II) whether they are treated with breast conserv-
ing therapy or mastectomy (EBCTCG 1995; Fisher 1995; Fisher
2002; Jacobsen 1995; Poggi 2003; Veronesi 1995; Van Dongen
2000; Veronesi 2002). Consequently, breast conservation has be-
come the preferred management option for these patients.
Breast conserving therapy consists of local excision of the tumour
(achieving clear margins) followed by radiation therapy. Radiation
therapy is given to sterilize tumour cells that may remain after
surgery. This practice is supported by data from detailed patholog-
ical examination of mastectomy specimens where residual tumour
was found more than two centimetres from the original tumour in
41% of patients (Holland 1985). Conventional radiation therapy
delivers 45 to 50Gy to the whole breast over five weeks followed by
a boost to the tumour bed (the most likely site of residual tumour
cells) of 10 to 16 Gy over one to two weeks. This prolonged du-
ration of treatment negatively impacts on quality of life (Whelan
2000) and contributes to the higher mastectomy rates observed
in women residing in rural and remote areas who wish to avoid
being away from home and family for extended periods (Schoen
2005).
Randomised studies have shown that addition of radiation ther-
apy decreases ipsilateral breast (same breast) recurrence rates from
30 to 40% (treated with lumpectomy alone) (Fisher 1995; Fisher
2002; Freeman 1981; Lagios 1983; Montgomery 1978) to 10 to
20% in 10 to 15 years of follow up (Fisher 1995; Fisher 2002). An
ipsilateral recurrence can either be a true recurrence of the origi-
nal cancer (typically arising in the same quadrant as the original
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tumour and known as local recurrence) or a second primary tu-
mour developing elsewhere in that same breast. Studies evaluating
ipsilateral breast tumour recurrence patterns show that new pri-
maries increasingly contribute to the rate of recurrence after five
to eight years while true recurrence rates stabilise (Krauss 2004;
Smith 2000). If radiation given to the whole breast (whole breast
radiation therapy) was successful in preventing the recurrence of
new primary cancer, the rate of such cancers in the treated breast
should be lower than the rate of development of cancers in the
other breast (contralateral breast cancer). This has not been found
in studies of ipsilateral breast tumour recurrence patterns (Krauss
2004, Smith 2000). Furthermore, more recent studies examining
primary and re-excision pathological specimens removed at the
time of breast conserving surgery revealed residual tumour less
than 10 and 15 mm from the primary tumour in 81% and 91%
of the specimens, respectively (Wallner 2004).
Thus, as most true recurrences occur in the same quadrant as the
original tumour and as whole breast radiation therapy (RT) does
not appear to protect against the development of new primary
cancer, investigators have begun to examine the role of partial
breast irradiation (PBI).
Description of the intervention
Partial breast irradiation (also known as less than whole breast
radiotherapy) refers to irradiation of a limited volume of breast
tissue around the tumour bed. It may be achieved by any of the
following techniques.
(1) Intracavitary brachytherapy or MammoSite® (applying ra-
dioactive sources directly into the cavity left after surgical removal
of the tumour either at the time of surgery or at a later date, the
latter requiring a second procedure).
(2) Interstitial brachytherapy (inserting catheters into the surgical
cavity and surrounding tissue to temporarily deliver radioactive
sources).
(3) Intra-operative techniques using electrons or X-rays at 50 kVp
(using a dedicated machine to deliver a very localised radiation
dose to the surgical cavity in the operating room or by moving the
patient with an open wound to the radiation machine, which may
be in a different part of the hospital).
(4) External beam radiotherapy using either three-dimensional
conformal RT (external beam radiation therapy delivered in the
post-operative setting to a volume of breast tissue around the tu-
mour cavity using a standard linear accelerator in a radiation on-
cology department) or other methods.
Conventional radiotherapy typically delivers a radiation dose of
2 Gy with each treatment. Partial breast irradiation techniques
deliver a larger than standard dose of radiationwith each treatment,
allowing the overall duration of treatment to be shortened. This
is termed accelerated partial breast radiation (APBI).
How the intervention might work
APBI will only be of benefit if it confers the same local control
benefit as standard whole breast radiotherapy with acceptable tox-
icity and cosmesis. APBI is currently an experimental therapy.
The use of APBI has a number of potential advantages including:
(1) a reduction in treatment-related toxicities, as a smaller volume
of breast tissue is irradiated;
(2) increased utilisation of breast conservation;
(3) a reduction in radiotherapy waiting times, a reduction in the
overall treatment duration of a common malignancy has the po-
tential to substantially impact on radiotherapy waiting times in
countries with strained resources (including UK, Canada, Aus-
tralia, New Zealand);
(4) a greater chance of preserving the breast should a recurrence
occur elsewhere in the breast;
(5) easier integration with chemotherapy schedules because RT
time will be shorter, thus avoiding delays.
The use of APBI has a number of potential disadvantages includ-
ing:
(1) an increased risk of local recurrence due to geographic miss
(either because treatment is delivered before full pathological ex-
amination is obtained or because of difficulty in reproducing the
target volume daily);
(2) increased late toxicity, the late effects of radiation are dependent
on the dose of radiation given at each treatment and as APBI
delivers a large radiation dose per fraction, late toxicity may be
increased with resultant poor cosmetic outcome (cosmesis);
(3) more patient inconvenience as some techniques may require a
second anaesthetic or a further invasive procedure;
(4) a number of techniques (eg interstitial and intracavitary
brachytherapy) require operator expertise and specialized equip-
ment which may not be available in all centres;
(5) invasive techniques of delivering APBI (eg interstitial and in-
tracavitary brachytherapy) may be associated with toxicity such as
infection and delays in wound healing. Scarring post-insertion of
interstitial brachytherapy catheters can negatively impact on cos-
metic appearance.
Why it is important to perform this review
APBI has the potential to change the pattern of practice for a com-
mon malignancy and thereby impact on resource utilisation, pa-
tient satisfaction and quality of life. However, as APBI is currently
an experimental therapy it must be thoroughly evaluated before
being adopted as the new standard of care for early-stage breast
cancer. The fact that the benefit versus risk profile of APBI is cur-
rently unknown makes it an ideal topic for a systematic review.
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O B J E C T I V E S
The objective of this review is to determine whether APBI has a
role in breast conservation therapy for early-stage breast cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials evaluating conservative surgery plus APBI ver-
sus conservative surgery plus whole breast radiotherapy. The com-
parisons must be un-confounded (that is treatments given to the
randomised groups must differ only in relation to the volume of
the breast radiated).Trials incorporating the use of adjuvant treat-
ments, such as chemotherapy,monoclonal antibodies or hormonal
therapy, are eligible if these other treatments were applied in ex-
actly the same way to both groups in the randomised trial. Pub-
lished and unpublished studies are eligible.
Studies in which partial breast irradiation is used as a boost fol-
lowing conventional external beam radiation therapy will not be
considered for inclusion.
Types of participants
Women with histologically confirmed early-stage breast cancer
who have had conservative surgery. Early breast cancer includes
tumours classified as AJCC stage T1-2N0-1M0 (Fleming 1997).
Surgery could include lumpectomy and wide local excision or
quadrantectomy, with or without axillary dissection, axillary sam-
pling or sentinal node biopsy. Women with a previous diagnosis
of breast cancer are not eligible for inclusion.
Types of interventions
Radiation delivered to the partial breast (PBI) using larger than
standard radiation dose per fraction such that the overall treatment
time is reduced (APBI). Any method of delivery of APBI will be
considered including but not limited to intracavitary brachyther-
apy or MammoSite®, interstitial brachytherapy, intra-operative
techniques such as electrons or X-rays at 50 kVp or external beam
radiation therapy using either three-dimensional conformal ther-
apy or other methods. Conventional breast radiation therapy is
delivered to the whole breast, including or not including the supra-
clavicular fossa and axilla, using standard fractionation (1.8 to 3.0
Gy per fraction) to deliver a total of 40 to 61 Gy at the reference
point. Treatment can include a boost (using electrons, interstitial
therapy, external beam or new techniques).
Types of outcome measures
Primary outcomes
Local recurrence in the ipsilateral breast and cosmesis.
Local recurrence will be defined as a recurrence of the same his-
tological type of cancer within the same quadrant of the breast as
the primary cancer.
Secondary outcomes
1. Overall survival (time fromdate of randomisation to death from
any cause, or number of deaths from any cause).
2. Toxicity (including acute and late effects of radiotherapy, che-
motherapy-related toxicity and surgical toxicity; individual proto-
col-based definitions).
3. New primary tumours in ipsilateral breast. A new primary will
be defined as a lesion arising in a quadrant of the breast that
is different from the original cancer or a tumour of a different
histological subtype occurring anywhere within the breast.
4. Cause-specific mortality (deaths due to breast cancer at five
years).
5. Distant metastases, in isolation or at the same time as local
recurrence (the occurrence of metastases at five years).
6. Relapse-free survival (length of time after treatment during
which no recurrence is found). Recurrence refers to breast cancer
in the ipsilateral breast or elsewhere in the body, excluding a new
breast cancer in the contralateral breast.
7. Subsequent mastectomy (ipsilateral partial mastectomy, modi-
fied radical mastectomy or radical mastectomy).
8. Compliance, defined as the number of women who commence
treatment with APBI or conventional EBRT and complete the
treatment course.
9. Costs (monetary costs of PBI versus EBRT) to women, govern-
ment and insurance companies.
10. Quality of life (using trial-specific instruments). The effects
of APBI and EBRT on global quality of life and the physical,
emotional and psychological domains.
11. Consumer preference - do women prefer APBI or EBRT given
the advantages and disadvantages of each approach?
Search methods for identification of studies
(1) Cochrane Breast Cancer Specialised Register
The specialised register maintained by the Cochrane Breast
Cancer Group will be searched (details of search strate-
gies used by the group for the identification of studies
and the procedure used to code references are outlined in
the group’s module (http://www.mrw.interscience.wiley.com/
cochrane/clabout/articles/BREASTCA/frame.html)). Studies on
the specialised register with keywords ’early’ and ’radiotherapy’
will be extracted for consideration.
(2) Electronic databases, no language restriction
(a) MEDLINE (host: OVID)
See Table 1.
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(b) Cochrane Central Register of Controlled Trials (CENTRAL)
(Wiley In-
terScience) (via internet http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/HOME)
(c) Cumulative Index to Nursing & Allied Health Literature
(CINAHL) (host: EBSCO)
(d) Current Contents (host: ISI Web of knowledge)
The MEDLINE search strategy will be modified to search the
above databases.
(3) Unpublished literature
We will search registers of ongoing clinical trials. These will in-
clude:
(a) US clinical trials registry (www.clinicaltrials.gov);
(b) International Standard Randomised Controlled Trial Number
Register (www.controlled-trials.com/isrctn);
(c) UKCCCR National Register of Cancer Trials (http://
212.219.75.236/ukcccr/).
(4) Grey literature
(a) SIGLE (http://stneasy.fiz-karlsruhe.de/dbss/
help.SIGLE.html)
We will contact researchers located from the grey literature and
unpublished literature to ask if they are aware of any other trials
on this topic.
Data collection and analysis
Selection of studies
All three authors (ML, BH, DF) will check the titles and abstracts
retrieved by the searches. Each review author will independently
assess the full text of the studies we think may be relevant to
the review, resolving differences in assessment by discussion. Trial
assessments will be performed with the results masked. In cases
where data are limited, or informationon studymethods is limited,
we will request further information from the study authors.
Data extraction and management
Three authors (ML, DF and BH) will perform data extraction,
with disagreements resolved by discussion. Data will be entered
into RevMan 4.2.8 for analysis. Where possible, we intend to ex-
tract data on tumour stage, nodal status, margin status, receptor
status, hormonal manipulation, treatment allocation and surgery
performed. The information extracted on radiotherapy will in-
clude overall treatment time, radiation dose, dose per fraction
and method of PBI. We will extract outcome data on local recur-
rence, deaths (all-cause and breast cancer deaths), new ipsilateral
primaries, mastectomy rate, distant metastases, treatment-related
toxicity (including that related to acute and late effects of radio-
therapy and to surgery), cosmesis, costs of treatment, consumer
preference and quality of life.
Assessment of methodological quality of included studies
Trials will be assessed to check that they meet the inclusion criteria
and the methodological quality will be assessed and graded. Any
disagreement will be resolved by discussion between the review
authors.
Methodological quality will be independently assessed by two re-
view authors (BH andML), the third author (DF) will be called in
to resolve any discrepancies. Studies will be assessed according to
the quality assessment tool based on the findings of Schulz 1995.
This assesses whether treatment allocation was randomised, treat-
ment allocation was concealed, patients were included in analyses
using intention-to treat principles and the adequacy of generation
of the allocation sequence. Because of the nature of interventions
used in the management of breast cancer, specifically those in-
volved in this review for example whether radiation is delivered
prior to chemotherapy, blinding of investigators or participants is
not possible, therefore, assessment blinding will not form part of
the quality assessment.
Sensitivity analyses will be performed on the basis of study quality.
The analysis will be performed both with and without trials of low
quality to assess the effect of quality on the results. Quality will be
assessed empirically. Studies meeting 3 of the 5 criteria in Schulz
1994 will be deemed high quality.
Measures of treatment effect
Results for dichomtomous outcomes will be presented as odds
ratios (OR) with 95% confidence intervals (CI) (Deeks 2004).
Results for continuous variables (such as quality of life) will be
summarised using the mean difference or the standardised mean
difference when different measurement scales are used (Deeks
2004).
Data synthesis (meta-analysis)
We will apply the intention-to-treat principle in analysing data
from the trials and determine a weighted average treatment effect
using the fixed-effect model to combine results, if appropriate (
Mantel 1959), with RevMan4.2.Wewill use theMantel-Haenszel
methods to calculate pooled results (Greenland 1985; Mantel
1959) if there is no significant heterogeneity, or otherwise the
random-effects model of DerSimonian and Laird.
Subgroup analysis and investigation of heterogeneity
If data are available, we may perform subgroup analyses to in-
vestigate whether the effects of using PBI or conventional breast
radiotherapy differ depending on nodal status, margin status, re-
ceptor status, hormonal manipulation or tumour stage. We will
assess heterogeneity both visually and statistically using the chi-
squared test of heterogeneity (Altman 1992; Walker 1988) and I
2 (Higgins 2002; Higgins 2003). The criterion for identification
of heterogeneity is a P-value less than 0.10 for the chi-squared
test, acknowledging the limitations of this process, and a value of
I2 greater than 50% . If we identify significant heterogeneity, the
reasons for it will be explored and we will make a cautious attempt
to explain the heterogeneity.
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Appendix 1. Search Strategy - Medline (Ovid)(1966 to present)
1.RANDOMIZED CONTROLLED TRIAL.pt
2. CONTROLLED CLINICAL TRIAL.pt
3. RANDOMIZED CONTROLLED TRIALS.sh
4. RANDOM ALLOCATION.sh
5. DOUBLE BLIND METHOD.sh
6. SINGLE BLIND METHOD.sh
7. or/1-6
8. (ANIMALS not HUMANS).sh
9. 7 not 8
10. CLINICAL TRIAL.pt
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab
14. PLACEBOS.sh
15. placebo$.ti,ab
16. random$.ti,ab
17. RESEARCH DESIGN.sh
18. or/10-16
19. 18 not 8
20. 19 not 9
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21. 9 or 20
22. exp breast neoplasms/
23. exp “neoplasms, ductal, lobular, and medullary”/
24. exp breast/
25. exp neoplasms/
26. 24 AND 25
27 (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$ or
intraductal$ or lobular or medullary)).mp.
28 exp mammary neoplasms/
29 (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$
or intraductal$ or lobular or medullary)).mp
30. or/22, 23,26-29
31. partial breast irradiation.sh,kw,ti,ab
32. partial breast.sh,kw,ti,ab
33. whole breast irradiation.sh,kw,ti,ab
34. whole breast radiotherapy.mp
35. less that whole breast rad$.mp
36. brachytherapy.sh,kw,ti,ab
37. high-dose-rate brachytherapy.sh,kw,ti,ab
38. accelerated partial breast irradiation.sh,kw,ti,ab
39. tumor bed boost.sh.kw.ti.ab
40. sole tumor bed irradiation.sh,kw,ti,ab
41. MammoSite.sh.kw.ti.ab
42. Breast Neoplasms/ rt.sh
43. Radiotherapy, Conformal/adverse events.sh
44. Radiotherapy, Conformal/methods.sh
45. Brachytherapy.sh
46. Balloon dilation.sh
47. Radiotherapy/.sh
48. or/31-47
49. 48 AND 30
50. 49 AND 21
WH A T ’ S N E W
Date Event Description
15 May 2008 Amended Converted to new review format.
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H I S T O R Y
Protocol first published: Issue 2, 2008
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by Dr Margot Lehman, Dr Brigid Hickey and Mr Daniel Francis
D E C L A R A T I O N S O F I N T E R E S T
Nil
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Princess Alexandra Cancer Collaborative Group, Australia.
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